Type of task force
2019 Annual Report
- Pulmonary Hypertension Master Class Course, 14-15 Oct 2019, King Faisal Specialist Hospital & Research Centre, Riyadh, KSA, in collaboration with University of California San Diego.
- 13th PVRI Annual World Congress on Pulmonary Vascular Disease, 31 January to 3 February 2019, Barcelona, Spain
- SAPH 12th Annual Conference, 14-16 February 2019, Manama, Bahrain (see following report)
- Middle East & North Africa Pulmonary Hypertension forum, 25-26 October 2019, Dubai, UAE
Research (current initiatives)
- EMEA CTEPH Registry: An international prospective registry investigating the epidemiology, diagnosis and treatment of CTEPH patients (chronic thromboembolic pulmonary hypertension) in EMEA countries (RAC #2161033)
- EXPERT, EXPosurE Registry RiociguaT in Patients with Pulmonary Hypertension (RAC # 2161038)
- Systematic Prospective Follow Up for Better Understanding of Clinical Characteristics of Patients with PH Disease (SAUDIPH) Registry (RAC # 2171148)
- Prevalence of Genetic Factors in Saudi Patients with Idiopathic Pulmonary Hypertension (RAC # 2161062)
- Transition of Bosentan to Macitentan in the treatment of Pulmonary Hypertension – comparison of clinical outcome (RAC # 2171190)
12th Annual Conference of the Saudi Association for Pulmonary Hypertension
SAPH2019, held in Bahrain on 14-16 February 2019, brought together physicians of the Middle East and North African countries and world experts in the field of pulmonary hypertension to engage and collaborate on the most advanced developments in the understanding and management of the disease.
The on-going collaboration between the Saudi Association for Pulmonary Hypertension (SAPH) and the Pulmonary Vascular Research Institute continues to be highly successful, as illustrated by the increased numbers of participants at SAPH2019, which included 30 international and regional faculty members, and 190 delegates (up from 120 in 2018).
The three-day event consisted of eight whole sessions on pulmonary hypertension, with 20-minute lectures followed by a 10-minute discussion. A Gala Dinner was held at the Ritz Carlton at the end of the second day.
An exceptional inaugural session, starting with an opening ceremony and welcome notes by SAPH2019 representatives, was followed by lively and thought-provoking discussion, highlighting new technological innovations and medical findings surrounding pulmonary vascular disease, which were reviewed and debated by all speakers.
These experts included PVRI invited speakers Professors Allan Lawrie (University of Sheffield) and Luke Howard (Imperial College London), as well various international speakers. Stimulating topics included:
- Pulmonary hypertension (PH) in paediatrics
- Congenital heart disease and PH
- Connective tissue disease and PAH
- 6th World PH Symposia
- Lectures from PVRI invited speakers
Case study presentations covered the entire spectrum of pulmonary arterial hypertension, including PAH in pregnancy and a case of portopulmonary hypertension (PPH). Three discussants, leading challenging case presentations, analysed each presented case.
The conference concluded with a session on chronic thromboembolic pulmonary hypertension (CTEPH), led by the most prominent speakers. The quality-driven programme promoted active participation from the delegates.
We would like to thank the two PVRI sponsored speakers, Allan Lawrie and Luke Howard, for their input and contributions.
To continue to enhance the quality of the conference, SAPH2020, to be held on 13-15 February 2020 in Riyadh, Saudi Arabia, will compile a programme consisting of the most influential topics and shared practices around the globe. It will also comprise an expert panel of prominent speakers, who will present their expertise in the field of pulmonary hypertension at national level.